Neogenomics (NEO) Non Operating Investment Income (2020 - 2021)

Neogenomics' (NEO) quarterly Non Operating Investment Income came in at $17.8 million in Q3 2021, down 81.61% on a QoQ basis from $96.5 million in Q2 2021.

Neogenomics (NEO) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Neogenomics (NEO) has 2 years of Non Operating Investment Income data on file, last reported at $17.8 million in Q3 2021.

  • Quarterly Non Operating Investment Income changed N/A year-over-year to $17.8 million in Q3 2021, while the trailing twelve-month figure through Sep 2022 was $17.8 million (down 84.99% YoY) and the FY2021 annual result came in at $109.3 million, up 2662.58% from the prior year.
  • Non Operating Investment Income retreated to $17.8 million in Q3 2021, from $96.5 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $96.5 million in Q2 2021 to a low of $4.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Thermo Fisher Scientific 213.92 Bn 209.86 Bn 8.34 Bn -
2 Danaher 140.37 Bn 136.02 Bn 3.61 Bn -
3 Idexx Laboratories 46.17 Bn 45.97 Bn 779.09 Mn -
4 Agilent Technologies 39.76 Bn 37.96 Bn 990.00 Mn -
5 Iqvia Holdings 39.41 Bn 37.33 Bn 1.44 Bn -
6 Natera 38.75 Bn 37.65 Bn 696.04 Mn -
7 Illumina 30.07 Bn 28.90 Bn 770.00 Mn -
8 Mettler Toledo International 28.62 Bn 28.56 Bn 650.22 Mn -
9 Quest Diagnostics 26.15 Bn 25.53 Bn 1.03 Bn -
10 Neogenomics 2.08 Bn 1.93 Bn 91.88 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 17.75 Mn
Sep 30, 2021 17.75 Mn
Jun 30, 2021 96.53 Mn
Jun 30, 2021 96.53 Mn
Dec 31, 2020 3.96 Mn
Dec 31, 2020 3.96 Mn